RedHill Biopharma

Company Overview

Snapshot

Founded in August 2009 by Dror Ben-Asher, RedHill Biopharma operates with 11–50 employees. The company has raised over $307.15 million across 23 funding rounds from 14 investors. In October 2025, RedHill's Talicia® secured a $4 million strategic investment and U.S. co-commercialization partnership deal with Cumberland Pharmaceuticals Inc.

Business overview

RedHill Biopharma is a specialty biopharmaceutical company focused on developing and commercializing proprietary drugs for gastrointestinal and infectious diseases. The company's core products include the FDA-approved drugs Talicia and Aemcolo, which are promoted in the U.S. by a dedicated sales team. RedHill also maintains an advanced R&D pipeline of late-stage clinical drug candidates aimed at addressing significant unmet medical needs within the Health Tech & Life Sciences sector, specifically targeting areas like gastroenterology and infectious disease.

Strategic signal

In September 2024, RedHill Biopharma's drug Talicia was listed as a first-line choice for H. pylori in new American College of Gastroenterology guidelines. This endorsement from a prominent medical authority validates the drug's efficacy and market position, signaling strong clinical acceptance and potential for increased adoption, which is a positive indicator for investors regarding future revenue growth and market share.

Company Intelligence Q&A

What was a significant recent commercial partnership for RedHill Biopharma?

In October 2025, RedHill's Talicia® secured a $4 million strategic investment and U.S. co-commercialization partnership deal with Cumberland Pharmaceuticals Inc. This agreement aims to expand the market reach of Talicia.

What was a key regulatory update for Talicia in 2024?

In September 2024, RedHill's Talicia® was listed as a first-line choice for H. pylori in new American College of Gastroenterology guidelines, indicating strong clinical validation and market positioning.

What was RedHill Biopharma's financial performance update in the first half of 2025?

In September 2025, RedHill Biopharma announced its financial results and operational highlights for the first half of 2025.

Did RedHill Biopharma receive any recent patent allowances?

In September 2023, RedHill announced a new USPTO Notice of Patent Allowance for Opaganib and an EU patent grant for RHB-102 (BEKINDA®).

What was a recent development regarding RedHill Biopharma's NASDAQ compliance?

In September 2024, RedHill Biopharma regained compliance with the Nasdaq minimum bid price requirement.